Skin lesions caused by bortezomib targeted therapy of multiple myeloma

Skin lesions caused by bortezomib targeted therapy of multiple myeloma

Bibliographic Details
Main Authors:	Michał Sobjanek, Martyna Sławińska, Anna Starzyńska, Małgorzata Sokołowska-Wojdyło
Format:	Article
Language:	English
Published:	Termedia Publishing House 2016-12-01
Series:	Przegląd Dermatologiczny
Online Access:	https://www.termedia.pl/Skin-lesions-caused-by-bortezomib-targeted-therapy-of-multiple-myeloma,56,28788,1,1.html

Similar Items

Bortezomib in the management of multiple myeloma
by: Jacob P Laubach, et al.
Published: (2009-09-01)

TREATMENT OF MULTIPLE MYELOMA WITH BORTEZOMIB
by: Veronika Kodre, et al.
Published: (2008-04-01)

Bortezomib for the treatment of multiple myeloma patients
by: Green, Colin, et al.
Published: (2009)

Bortezomib for the treatment of multiple myeloma patients
by: C Green, et al.
Published: (2009-06-01)

Tuberculosis meningitis in patient with multiple myeloma during bortezomib-containing therapy
by: Yu-Chen Tsai, et al.
Published: (2016-10-01)

Effectiveness of bortezomib and bortezomib-containing programs FOR the treatment of recurrent and resistant multiple myeloma
by: T A Mitina, et al.
Published: (2010-07-01)

Bortezomib Treatment Modulates Autophagy in Multiple Myeloma
by: Giuseppe Di Lernia, et al.
Published: (2020-02-01)

Clinical outcomes of bortezomib-based therapy in myeloma.
by: Faouzi Djebbari, et al.
Published: (2018-01-01)

Cytokine and Chemokine Profile in Patients with Multiple Myeloma Treated with Bortezomib
by: Paweł Robak, et al.
Published: (2020-01-01)

Chalazia development in multiple myeloma: a new complication associated with bortezomib therapy
by: Charles Yun, et al.
Published: (2015-06-01)

Dorsal Column Degeneration after Bortezomib Therapy in a Patient with Multiple Myeloma
by: Tatsuro Joh, et al.
Published: (2009-10-01)

Clinical Assessment of Bortezomib for Multiple Myeloma in Comparison with Thalidomide
by: Mitsutoshi Satoh, et al.
Published: (2011-02-01)

Update on the optimal use of bortezomib in the treatment of multiple myeloma
by: Mohan M, et al.
Published: (2017-03-01)

Another, new dermatosis in the spectrum of pigmented purpuric dermatoses or atypical variant of lichen aureus?
by: Martyna Sławińska, et al.
Published: (2017-12-01)

Bortezomib-induced hyponatremia: tolvaptan therapy permits continuation of lenalidomide, bortezomib and dexamethasone therapy in relapsed myeloma
by: N. O’Connor-Byrne, et al.
Published: (2019-02-01)

Bortezomib therapy in a real-world setting in patients with relapsed or refractory multiple myeloma
by: Shang-Yi Huang, et al.
Published: (2019-01-01)

Three cases of presumed pneumocystis pneumonia in patients receiving bortezomib therapy for multiple myeloma
by: Christopher D. Swan, et al.
Published: (2014-01-01)

The role of АВС transporters in drug resistance to bortezomib in multiple myeloma
by: L. A. Laletina, et al.
Published: (2019-04-01)

Herpes zoster in multiple myeloma patients during bortezomib treatment
by: I. N. Nazarova, et al.
Published: (2014-07-01)

Bortezomib Prescription Pattern for the Treatment of Multiple Myeloma by Hematologists in Nigeria
by: Kaladada I. Korubo, et al.
Published: (2017-10-01)

Efficacy of Bortezomib as First-Line Treatment for Patients with Multiple Myeloma
by: Utkarsh Painuly, et al.
Published: (2013-02-01)

Efficacy and tolerability of bortezomib and dexamethasone in newly diagnosed multiple myeloma
by: Mir Sadaqat Hassan Zafar, et al.
Published: (2018-01-01)

Efficacy of Bortezomib as First-Line Treatment for Patients with Multiple Myeloma
by: Utkarsh Painuly, et al.
Published: (2013-01-01)

Expression of GITR Enhances Multiple Myeloma Cell Sensitivity to Bortezomib.
by: Yinghao Zhao, et al.
Published: (2015-01-01)

Subcutaneous bortezomib for multiple myeloma treatment: patients’ benefits
by: Petrucci MT, et al.
Published: (2014-07-01)

Pharmacovigilance of patients with multiple myeloma being treated with bortezomib and/or thalidomide
by: T.B.M. Castro, et al.
Published: (2016-01-01)

Herpes zoster in multiple myeloma patients during bortezomib treatment
by: I. N. Nazarova, et al.
Published: (2014-07-01)

Cost-effectiveness of bortezomib for multiple myeloma: a systematic review
by: Chen W, et al.
Published: (2016-05-01)

Bortezomib resistance in multiple myeloma is associated with increased serine synthesis
by: Esther A. Zaal, et al.
Published: (2017-08-01)

Tumor microenvironment-targeted nanoparticles loaded with bortezomib and ROCK inhibitor improve efficacy in multiple myeloma
by: Cinzia Federico, et al.
Published: (2020-11-01)

New bortezomib-based combination therapy for elimination of myeloma cells
by: Voll RE, et al.
Published: (2009-02-01)

Short Term Renal Outcome of Bortezomib Based Therapy in Patients with Multiple Myeloma Requiring Dialysis
by: Alok Kumar Pandey, et al.
Published: (2020-01-01)

Successful Use of Cyclophosphamide as an Add-On Therapy for Multiple Myeloma Patients with Acquired Resistance to Bortezomib or Lenalidomide
by: Shigeki Ito, et al.
Published: (2013-01-01)

Safety and Efficacy of Doxorubicin, Cyclophosphamide, Bortezomib, Dexamethasone and Lenalidomide Followed by Bortezomib Consolidation as First-Line Therapy in Patients with Newly Diagnosed Multiple Myeloma
by: Kristian T. Andersen, et al.
Published: (2020-01-01)

The Value of Serum MicroRNA Expression Signature in Predicting Refractoriness to Bortezomib-Based Therapy in Multiple Myeloma Patients
by: Paweł Robak, et al.
Published: (2020-09-01)

Efficacy of lenalidomide, bortezomib, and prednisolone in patients with relapsed or refractory multiple myeloma
by: T. A. Мitinа, et al.
Published: (2015-12-01)

HDAC6-Selective Inhibitor Overcomes Bortezomib Resistance in Multiple Myeloma
by: Sang Wu Lee, et al.
Published: (2021-01-01)

Clinical Outcome of Bortezomib Retreatment in Patients with Relapsed or Refractory Multiple Myeloma
by: Jae-Sook Ahn, et al.
Published: (2014-01-01)

The choice of regimens based on bortezomib for patients with newly diagnosed multiple myeloma.
by: Jingsong He, et al.
Published: (2014-01-01)

Bortezomib a safety treatment for patients with Multiple Myeloma and Cystic Fibrosis
by: Fabiana Gentilini, et al.
Published: (2012-01-01)

Cannot write session to /tmp/vufind_sessions/sess_j0hdbgscbbiv3obf2c710u0g9u